Bayer buys US biotechnology company for € 3,3 billion

The German company will pay half of the money, while the other half will be paid according to the goals achieved by Asklepios BioPharmaceutical, which bets on genetic therapies and treatments against Parkinson's disease and heart problems.

Bayer bought the American biotechnology company Asklepios BioPharmaceutical for € 3,3 billion, thus targeting batteries for gene therapies with the help of modified viruses, reports the agency "Reuters" this Monday, October 26.

The German company will pay half of the money, while the other half will be paid according to the objectives achieved by the North American company, based in North Carolina.

Among the projects in the greatest development phase of AskBio are the first voluntary tests on a potential treatment against Pompe's disease, a rare genetic disease that causes the accumulation of a sugar molecule inside the cells.

The biotechnology company has also developed projects to combat Parkinson's disease or heart failure problems. A potential treatment against Duchenne muscular dystrophy, created by AskBio, is currently being developed in clinical trials by Pfizer.

Recommended

Public transport between West and Lisbon with reinforcement of 600 thousand euros

In the dispatch, the Minister for the Environment and Climate Action, João Matos Fernandes, justifies that “the pandemic and the need to ensure public health protection measures imply the determination of limitation impositions and adjustments to the operation of public passenger transport, namely the level of vehicle occupancy, which is limited to 2/3 of the capacity ”.

From Sword Health to ComparaJá. The 25 largest Portuguese scale-ups of 2020

This year's top grossed a total of 117.818.347 euros in financing. The most recent report “Scaleup Portugal”, prepared by BGI and EIT Digital, points to a “gap between corporate and the startup ecosystem”.

New Bank. PSD admits it can approve supplementary OE in 2021 with transfer after audit by the Court of Auditors and if the “amount is due”

After the PSD joined the Left Bloc on Wednesday to make it possible to eliminate the authorization for transfers to the Novo Banco, Parliament is today the stage for a lively debate about the banking institution.
Comments